España
India
Italia
대한민ęµ
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise
Contribute
España
India
Italia
대한민ęµ
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Recent
Markets
Hospira
A Look At All Of Pfizer's Acquisitions Over The Past 2 Years
Pfizer Receives FDA Approval For Cheaper Version Of Johnson & Johnson's Top Drug Remicade
Pfizer Reports Better-Than-Expected Q4, Shares Dip Lower
Pfizer Receives FDA Approval For Cheaper Version Of Johnson & Johnson's Top Drug Remicade
Pfizer Reports Better-Than-Expected Q4, Shares Dip Lower
Why M&A Doesn't Make Sense For Pfizer Anytime Soon
Mizuho Analyst On The Fence At Medicines Co. Pending Patent Appeal
Why M&A Doesn't Make Sense For Pfizer Anytime Soon
|
Mizuho Analyst On The Fence At Medicines Co. Pending Patent Appeal
|
Fresenius SE, Permira Interested In Acquiring Danone's Medical Unit
|
Wedbush Initiates Coverage On Cubist Pharmaceuticals
|
Read More...
Hospira Recent News
#PreMarket Primer: Monday, July 28: Tension Between U.S. And Israel On The Rise
|
Market Wrap For April 1: S&P 500 Hitting New All-Time High Not An April Fools' Joke
|
Top Trending Tickers On StockTwits For February 12
|
Barron's Recap (2/9/12): Best Fund Families
|
Caterpillar, Discover Financial and Other Illinois Primary Stock Picks
|
Goldman Sachs Maintains Neutral on Hospira
|
Citi Maintains Sell Rating on Hospira
|
Morgan Stanley Reiterates Equal-Weight on Hospira
|
J.P. Morgan Maintains OW Rating on Hospira Following Management Meeting
|
Goldman Sachs Downgrades HSP To Neutral
|
UPDATE: J.P. Morgan Color On HSP Target Increase
|
JP Morgan Raises PT On Hospira To $66
|
Citigroup Downgrades Hospira To Sell, PT to $54
|
HSP's 1Q11 IMS Sales Are Improving, Morgan Stanley Reports
|
Morgan Stanley Increases HSP 1Q11 Estimates
|
Goldman Sachs Maintains Buy Rating On Hospira
|
Citigroup Upgrades Hospira To Hold, PT To $52
|
Goldman Sachs Lowers PT on Hospira to $59 (HSP)
|